Science / People / Progress
Accessed: 12.11.2019
Date issued: 14 April 2020
The Global Fund is committed to ensuring that input from those closest to and living with HIV, tuberculosis and malaria are included in every funding request to the Global Fund. Their input is critical to ensuring that programs are effective and designed to help those m...ost impacted.
Inclusive country dialogue and the engagement of civil society, communities, and key and vulnerable populations in the development of funding requests remains a requirement for receiving financing from the Global Fund.
more
March 2020
The number of African Union Member States reporting COVID-
19 cases is increasing and there is a likelihood of community transmission. The WHO recently modified the COVID-19 suspect case definition to include severe acute respiratory infection and advises testing of all severe acute r...espiratory illness (SARI) cases.1 However, many Member States have not yet started implementing these changes, they are still focussing surveillance efforts on individuals with travel history to an area with local COVID-19 transmission. This means patients with similar symptoms, but no apparent contact, may not
be investigated.
more
Contact tracing is a core public health response to COVID-19.Other measures include active case finding or physical distancing. In order to trace a contact, we first need to define what a ‘contact’ is.
This brief document compiles existing material related to mental health and psychosocial support (MHPSS) for the COVID-19 crisis, as well as other resources that can be applicable to the context. Documents are divided into different sections, based on the ‘’spaces of new vulnerability” inheren...t to some IOM programmes although many of them are applicable to other areas. They cover both mainstreaming of MHPSS and specific actions.
MHPSS managers will also find guidance on how to address the less technical and more managerial and programmatic issues related with the pandemic, including programme redefinition, surge capacity and how to manage demands to provide staff support to colleagues in the same missions
more
The global pandemic has highlighted fragility in international supply chains and the dependency of many African countries on imported personal protective equipment (PPE). Market pressures have also increased prices for imported supplies and put additional pressure on areas with limited resources for... procurement. There is an urgent operational need to develop the domestic capacity to supply PPE from within the African continent. There is huge variation in Member
States industrial manufacturing capacity and the regulatory and testing capacity of government agencies at present. Growing number of companies, including micro- and small-medium enterprises, have responded by repurposing, albeit temporarily, to manufacture an assortment of PPEs. This workshop aims to bring together government representatives, industry, and subject matter experts on material testing and standards to promote the development of domestic production of safe and effective PPE made in Africa.
more
From Participation to Partnerships (September 2020)
Despite the COVID-19 challenges, children around the world have found meaningful ways to support and protect their peers, families, and communities. Children are on the frontlines of innovative responses and are working closely with their adult al...lies. The leadership demonstrated through these child-adult partnerships is the underlying inspiration for this guide.
more
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021
“The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...ed below.
This document has been updated: Version 15 March 2022.
more
The paper provides the rationale for these recommendations, which are based on analyses of data from the TRACT trial.
Climate change is resulting in poorer health outcomes, increasing mortality and is a driver of health inequities. However, health is well placed to be a significant part of the solution; the positive health impacts from stronger climate change action can motivate stronger global ambition; health sys...tems which are resilient to climate change can help protect their populations from the negative impacts (in the short and longer terms); and sustainable low carbon health systems can make a substantial contribution to reducing national and global emissions.
This fact sheet on climate change and health is part of the Climate Fast Facts series of the United Nations Climate Action team.
more
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
Vaccination programmes against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. Administration of both vaccines during the same visit has potential advantages. This document presents the evidence related to coadministration of Covid-19 and influenza vacc...ines and the interim guidance.
more
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).